Recent studies demonstrate that approximately 90% of HIV-associated CD4 cell death is caused by pyroptosis of uninfected cells rather than by apoptosis of infected cells. This pro-inflammatory cascade is demonstrated most strongly in lymphoid tissues, where concentrations of both HIV and CD4 cells are particularly high. Current treatment of HIV utilises chemical drugs to inhibit viral replication. However, with a high number of viruses produced per infected cell, coupled with the numerous mutations associated with HIV’s reverse transcriptase mechanism, HIV is incredibly adaptive against current medication. The proposed research aims to develop a “decoy CD4 cell”, whereby the membrane would still contain the characteristic proteins and receptors of CD4 cells, but it would lack the fundamental organelles required for HIV replication. Thus, HIV would continue to infect decoy cells, but would be rendered harmless upon infection. Throughout the body, decoy cells would work as sponges in situ to soak up large portions of HIV and allow for functional restoration of CD4 cell levels. To develop the decoy cell, mechanisms that allow erythrocytes to shed their nucleus and ribosomes would be investigated first. Then, through gene therapy, these mechanisms could be incorporated into CD4 cells. Efficacy in containing HIV would then be screened for in vitro, then analyzed in vivo by mouse model, and then finally, in clinical trials. If all is successful, this new biotechnology could provide promising implications for finding a functional cure for HIV, as well as other similar retroviruses.